

### Transcript Details

This is a transcript of an educational program. Details about the program and additional media formats for the program are accessible by visiting: <https://reachmd.com/programs/medical-industry-feature/enhancing-your-aesthetic-skillset-a-new-training-and-educational-hub/13227/>

### ReachMD

www.reachmd.com  
info@reachmd.com  
(866) 423-7849

---

### Enhancing Your Aesthetic Skillset: A New Training and Educational Hub

#### Announcer:

Welcome to ReachMD.

This medical industry feature, titled "Enhancing Your Aesthetic Skillset: A New Training and Educational Hub" is sponsored by Allergan Medical Institute®.

Here's your host, Dr Jennifer Caudle.

#### Dr Caudle:

Healthcare providers in the aesthetics and dermatology space have plenty of products available to help meet their patients' facial needs, but we also know there is an ongoing need for manufacturers to consistently offer training to further aesthetics education. So, what can be done to bring training to a wider range of physicians, beyond just beginners? This is ReachMD, and I'm your host, Dr Jennifer Caudle, and joining me to discuss a new educational and training hub are Jeran Wadlow and Josh Elmassian. Jeran is an Associate Director of Digital at Allergan Medical Institute® in Irvine, California. Jeran, thank you so much for being here today.

#### Jeran:

Thank you so much, Dr Caudle. I am so excited to share some information with our audience today.

#### Dr Caudle:

Thank you. And joining us a bit later is Josh Elmassian, who's the Director of JUVÉDERM® U.S. Commercial Business and Marketing at Allergan Aesthetics, also in Irvine. Josh, it's great to have you with us.

#### Josh:

Thank you so much, Dr Caudle, for hosting us today. We look forward to, um, sharing some great information with our viewers.

#### Dr Caudle:

Thank you. Now Jeran, why don't we start off by discussing unmet needs in aesthetics, and how you've helped to address these needs?

#### Jeran:

Absolutely. So, to address the need for manufacturers to further the aesthetics education continuum, Allergan Aesthetics saw the importance of providing a personalized approach to training, and developing education that was customized to where a healthcare provider is in their aesthetics career. That strategy really allowed us to fill the void, and offer training to a wider range of providers, by spanning the entire education continuum. So in response to that need for more robust aesthetic education, Allergan Medical Institute®, or AMI for short, launched in 2017 as a global education brand. Our portfolio of training spans those who are new to aesthetics and covers the milestones through expert level HCPs, or healthcare providers.

In 2022 alone, AMI trained over 150,000 healthcare providers worldwide, and we're continuing to expand that reach. We also offer educational courses on the business of aesthetics for practice owners and administrative staff, and our goal is really to advance the education in several fields, including facial aesthetics, plastic and regenerative medicine, body contouring, skincare, and even business.

#### Dr Caudle:

Thanks so much for that background. Now as I understand it, you've launched a new website. Can you tell us about this?

**Jeran:**

Sure. So, naturally we want users of our products to have the best education, so AMI has invested in achieving desired patient outcomes by focusing on clinical proficiency and meeting diverse patient needs. AMI Online is the only platform that provides personalized training on several of the product pillars that I just mentioned, and we're continuing to expand our offerings.

Overall, our core mission is to educate and empower the aesthetics community with evidence-based and progressive training curricula.

And as the Allergan Aesthetics portfolio grows, we'll continue to add even more training content and capabilities to this platform. You can find us at [amionline.com](http://amionline.com), and we're accessible from any internet-connected device.

**Dr Caudle:**

Thank you, Jeran. And now can you start walking us through the features of the site?

**Jeran:**

Sure. When a healthcare provider logs in and registers on the site for the first time, they're going to be asked to take a survey based on their experience as an aesthetic injector. Those survey responses help create what we call "site logic," and that's what will serve up relevant and personalized content to each individual user, based on their experience level.

This is the initial screen that users will see when they log in. From here, users will be able to choose between a couple of different pathways for their educational content. They can go into AMI Product Training, or they can go into AMI Educational Resources. The product training side contains information on our products, so I'm going to click there for the purposes of this demo.

On the dashboard, we've got a list of training courses, and any current notifications or reminders will show up here as well.

It's also important to note that the site is designed to continuously update a user's learning preference, so that they can receive the most customized content for them. At any time, the healthcare provider can actually go back and update their personalization survey, under "Update Learning Preferences," and as a user training path evolves, they can update the survey based on their experience and learning journey, and that will then shape the future content that is served up to that user.

Now let's take a look at the menu on the left-hand side. Here's where you can navigate to your learning and events, resources, activities, and learning history.

And here, on that learning and events page, users can search based on the type of content, or also by product. Those who've completed their personalization survey will first see the content that's been recommended to them before other content appears.

**Dr Caudle:**

Now before we switch over to Josh, is there anything else you'd like to point out on the site?

**Jeran:**

Yes, I have just a couple more quick things to share with our audience, so let's go to the learning history section of the site. This is where a user can see any courses they've previously taken, and can also access any completion certificates they might have available. And one final thing I'd like to show our audience is how to access that unbranded content I referenced earlier.

Up here, on the top right, users can click on "Educational Resources," which will take them to that unbranded portion of the site, where they can find anatomy education, consultation resources, and things like that.

**Dr Caudle:**

Thank you. For those of you who are just tuning in, you're listening to ReachMD. I'm your host, Dr Jennifer Caudle, and joining me today to discuss the new AMI Online Learning Platform from Allergan Aesthetics, and the latest training content available for a jawline filler, JUVÉDERM® VOLUX® XC, are Jeran Wadlow and Josh Elmassian from Allergan Aesthetics.

So, turning over to you now, Josh, as you represent the JUVÉDERM® Collection of Fillers. Now that we've discussed the features of AMI Online, what are some of the JUVÉDERM® content a user may expect to see on AMI Online?

**Josh:**

Of course, Dr Caudle. Thank you so much. So, um, first as some background, in January 2023, we launched our latest product, JUVÉDERM® VOLUX® XC, indicated for subcutaneous and/or superperiosteal injection for improvement of jawline definition in adults over the age of 21 with moderate to severe loss of jawline definition. So, uh, this product—it's really unique, as it's the only hyaluronic acid dermal filler that's designed for smooth, natural-looking and long-lasting results in the jawline. And the AMI Online is supporting this product launch with a variety of digital courses specific to jawline, including jawline anatomy, assessment, and injection.

So, let's toggle back to AMI Online, to show you where that lives, and how we filter for that. And you can see here that we have courses including Jawline Anatomy, Assessment, and Injection. So, something else that I'd like to note is AMI will be making their webcast content available for users, and this is really exciting because our On-Demand webcast will now be available on AMI Online, and we've actually started this, with the JUVÉDERM® VOLUX® XC webcast that was broadcast live in February 2023. So, this recording is now part of the JUVÉDERM® training content.

So, expanding on that, we also have broader course offerings, such as Facial Anatomy with cadaver examples, JUVÉDERM® Collection Science and Rheology, and courses that speak to using JUVÉDERM® products in the lower face, and courses specific to JUVÉDERM® VOLUMA® XC in the mid-face and chin. So, we know, right, that many areas are not treated in isolation. With AMI Online, specifically with the JUVÉDERM® Collection of Fillers, these courses fulfill our goal that Jeran mentioned earlier, right, of providing comprehensive education to our healthcare providers for improved patient outcomes.

**Dr Caudle:**

Thank you, Josh. And, can you tell us how AMI Online, so far, is helping healthcare providers who want education and training on your filler products?

**Josh:**

Absolutely. So, AMI Online has shifted what it means to have an on-demand, personalized learning journey. Our users are very busy in their practices, uh, but they're also eager to learn, and our courses fit into any schedule.

So, whether users wanna learn about the rheology of products within the JUVÉDERM® collection, how to inject a particular area of the face, or even freshen up on anatomy training, this site offers multiple education pathways for all levels of learning.

**Dr Caudle:**

Now, unfortunately, we're almost out of time for today, but before we close, Josh, what would you like to leave with our audience?

**Josh:**

So, we're designing AMI Online to meet you where you are in your educational journey, which is critical to patient safety and outcomes. Don't just go down your educational pathway on your own. Rather, we'd like users to be proactive with our resources, and reach out to your Allergan Aesthetics business development manager to supplement continuing educational needs.

**Dr Caudle:**

And Jeran, we'll end with your final thoughts.

**Jeran:**

Thank you, Dr Caudle. I 100% mirror Josh's thoughts, and I'll add that if you haven't gone to AMI Online yet, we welcome you to join this learning community. And if you've already registered on the site, please keep coming back, so you can keep up with the latest content. We're adding new training and educational resources all the time, and our goal is to be your partner in medical aesthetics education. Again, you can join us at [www.amionline.com](http://www.amionline.com) to start your personalized learning journey with us.

**Dr Caudle:**

Thank you so much. And I'd like to thank my guests, Jeran Wadlow and Josh Elmassian, for introducing us to Allergan Medical Institute®, and showcasing its unique features. Jeran and Josh, it was great speaking with you today.

**Jeran:**

Thank you for having us, Dr Caudle.

**Josh:**

Yes, thank you so much.

**Dr Caudle:**

Well, thank you both.

I'm your host, Dr Jennifer Caudle, and before we close, let's take a moment to review the Indications and Important Safety Information.

**Announcer:**

**JUVÉDERM® VOLUX® XC and JUVÉDERM® VOLUMA® XC Important Information**

**INDICATIONS**

JUVÉDERM® VOLUX® XC injectable gel is indicated for subcutaneous and/or supraperiosteal injection for improvement of jawline definition in adults over the age of 21 with moderate to severe loss of jawline definition.

JUVÉDERM® VOLUMA® XC injectable gel is indicated for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face and for augmentation of the chin region to improve the chin profile in adults over the age of 21.

### IMPORTANT SAFETY INFORMATION

#### CONTRAINDICATIONS

These products should not be used in patients who have severe allergies, marked by a history of anaphylaxis or history or presence of multiple severe allergies, and should not be used in patients with a history of allergies to Gram-positive bacterial proteins or lidocaine contained in these products.

#### WARNINGS

- Do not inject into blood vessels. Introduction of these products into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting soft tissue fillers. For example, after insertion of the needle and just before injection, the plunger rod can be withdrawn slightly to aspirate and verify the needle is not intravascular. Inject the product slowly, and apply the least amount of pressure necessary. Rare, but serious, adverse events associated with the intravascular injection of soft tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, or unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and, possibly, evaluation by an appropriate healthcare professional specialist should an intravascular injection occur
- Product use at specific sites in which an active inflammatory process (skin eruptions such as cysts, pimples, rashes, or hives) or infection is present should be deferred until the underlying process has been controlled

#### PRECAUTIONS

- To minimize the risk of potential complications, these products should only be used by healthcare professionals who are knowledgeable about the anatomy and the product(s) for use in indicated area(s), and who have appropriate training in facial anatomy, vasculature, safe injection techniques, and identification and management of potential adverse events, including intravascular complications
- The potential risks of soft tissue injections should be discussed with patients prior to treatment to ensure they are aware of signs and symptoms of complications
- The safety and effectiveness for the treatment of anatomic regions other than indicated areas for each product have not been established in controlled clinical studies
- The safety for use of these products in patients with known susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders has not been studied
- The safety for use of JUVÉDERM® VOLUMA® XC has been established in patients between 35 and 65 years of age for cheek augmentation and in patients between 22 and 80 years of age for chin augmentation. The safety for use of JUVÉDERM® VOLUX® XC in patients under 22 years has not been established
- The safety for use during pregnancy and in breastfeeding females has not been established
- Dermal filler implantation carries a risk of infection. Follow standard precautions
- Dermal fillers should be used with caution in patients on immunosuppressive therapy
- Patients taking medications that can prolong bleeding (such as aspirin, nonsteroidal anti-inflammatory drugs, and warfarin) may experience increased bruising or bleeding at treatment sites
- If laser treatment, chemical peel, or any other procedure based on active dermal response is considered after treatment, or before skin has healed from a procedure prior to treatment, there is a possible risk of eliciting an inflammatory reaction at the injection site
- The safety for use of JUVÉDERM® VOLUMA® XC injectable gel in patients with very thin skin in the mid-face has not been established
- The safety for use of JUVÉDERM® VOLUMA® XC with cannula for cheek augmentation has not been established in patients with Fitzpatrick Skin Types V and VI
- JUVÉDERM® VOLUMA® XC was not evaluated in subjects with significant skin laxity of the chin, neck, or jaw in the chin

augmentation study

- The effect of JUVÉDERM® VOLUMA® XC injection into the chin on facial hair growth has not been studied
- Patients may experience late-onset adverse events with use of injectable gel implants, and late-onset nodules with use of JUVÉDERM® VOLUMA® XC
- Based on preclinical studies, patients should be limited to 20 mL of any JUVÉDERM® injectable gel per 60 kg (132 lb) body mass per year. The safety of injecting greater amounts has not been established
- Injection of more than 9 mL of JUVÉDERM® VOLUX® XC for improvement of jawline definition has not been studied

### ADVERSE EVENTS

The most common reported side effects for JUVÉDERM® injectable gels were redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration, and itching. The majority were mild or moderate in severity.

**To report an adverse reaction with any product in the JUVÉDERM® Collection, please call Allergan® Product Support at 1-877-345-5372. Please visit [JuvedermDFU.com](http://JuvedermDFU.com) for more information.**

Products in the JUVÉDERM® Collection are available only by a licensed physician or properly licensed practitioner.

### Reference:

1. JUVÉDERM® VOLUX™ XC Directions for Use, July 2022.

PRT163298 07/23